Stem Cells Archives | Page 184 of 200

Commence Bio Focuses on Mesenchymal Stem Cells (MSCs) as Immunotherapies with New Website and Corporate ID

January 4, 2016 By Cade Hildreth, Founder & President Leave a Comment

Commence Bio is an intriguing company that has recently entered the mesenchymal stem cell (MSC) marketplace. Commence Bio came across my radar screen earlier this year right around the time that it announced the name change, as highlighted in the company press release below.

Specifically, Commence Bio is a pre-clinical stage biotechnology company that was “founded on the vision that cancer and inflammatory diseases can be optimally treated by rebooting patients’ immune systems with a new class of medicinal stem cells: MSC1 & MSC2.” The company is now developing a therapeutic pipeline, as well as offering research products (MSC1 and MSC2 cells and media). The concept around which the company is based is that its proprietary technology programs naïve MSCs so that they can localize to sites of immune dysfunction.

[Read more…]

Top Five Mesenchymal Stem Cell (MSC) Influencers on Twitter

January 4, 2016 By Cade Hildreth, Founder & President Leave a Comment

This post identifies the top five mesenchymal stem cell (MSC) influencers on Twitter. This assessment was conducted using the social analytics platform Topsy.com and the hashtag “#mesenchymal”.

As you can see from the figure below, the first place Twitter account is “MesenchymalCellNews” (@mesenchymal_cell), which self-describes itself as the “online resource for the mesenchymal cell community.” Interestingly, the second place Twitter account is “Cord Blood News” (@cord_blood_news). This account holder appears to be posting about topics pertaining to both cord blood and cord tissue, as MSCs are prevalent in large quantities in cord tissue, also called Wharton’s Jelly. Of course, I am pleased to have our account, “BioInformant” (@StemCellMarket), appear third on this list, because our Twitter feed is dedicated to posts about stem cell industry trends. [Read more…]

Cord Tissue Storage Impacted by the Global Mesenchymal Stem Cell (MSC) Market

December 30, 2015 By Cade Hildreth, Founder & President Leave a Comment

For our clients in the cord blood banking sector, we highly recommend that you review the report, “Mesenchymal Stem Cells – Advances & Applications.” This MSC report will uniquely inform you about opportunities related to cord tissue storage and future applications with cord tissue derived MSCs.

Remember, to benefit from the global MSC market, you need to anticipate and serve the needs of your clients – or other cord blood banks will.

Key questions answered in the report are:
(Regenerative Medicine = RM; Cell Therapy= CT)

[Read more…]

Ocata Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells

December 29, 2015 By Cade Hildreth, Founder & President Leave a Comment

With a market capitalization of more than $350 million, Ocata Therapeutics is a major player in the stem cell space. Based in Marlborough, Massachusetts, it is a clinical stage biotech company that develops a range of regenerative therapies for the treatment of ophthalmologic conditions. By 2010, Ocata Therapeutics (at the time called “Advanced Cell Therapy”) began experimenting with induced pluripotent stem cells (iPSCs). This was only four years after research and experimentation using mouse cells at Kyoto University first generated iPSCs in 2006, and only three years after a series of follow-up experiments done at Kyoto University successfully transformed human adult cells into iPSCs in 2007.

Due to concerns with the use of iPSCs for therapeutic applications, the company shifted its approach to using human embryonic stem cells (hESCs) for clinical trial purposes, as well as other pluripotent cell types.

In major news released on December 28, 2015, Ocata Therapeutics stated in a company press release that “early research was published in the journal PLOS One (online, December 21, 2015) by Ocata and its collaborators at the University of Miami, UCSD, and Stanford University…presenting a method for generating scalable amounts of human embryonic stem cell derived corneal endothelial cells (hESC-CEC).” [Read more…]

Methodology for Determining the Top 10 MSC Articles

Key questions answered in the report are: (Regenerative Medicine = RM; Cell Therapy= CT)

Key questions answered in the report are:
(Regenerative Medicine = RM; Cell Therapy= CT)